Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab vs MTX in Pediatric Psoriasis
NCT01251614Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2010
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in plaque psoriasis (3 arms), sponsored by AbbVie Inc. Primary endpoints: Proportion of Participants Achieving PASI 75 Response at 16 weeks and Proportion of Participants Achieving PGA Cleared or Minimal at 16 weeks. Started Dec 2010; status: completed.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01251614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251614.